PCSK9: an emerging target for treatment of hypercholesterolemia

Author： Duff Christopher J   Hooper Nigel M  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.15, Iss.2, 2011-02, pp. : 157-168

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies

By  

Current Pharmaceutical Design, Vol. 19, Iss. 17, 2013-05 ,pp. : 3161-3172

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia

By  

Current Pharmaceutical Design, Vol. 23, Iss. 10, 2017-05 ,pp. : 1484-1494

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia

By Wierzbicki Anthony S   Hardman Timothy C   Viljoen Adie  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 5, 2012-05 ,pp. : 667-676

Informa Healthcare

Access to resources Recommend Favorite

MMP-9, a Potential Target for Cerebral Ischemic Treatment

By  

Current Neuropharmacology, Vol. 7, Iss. 4, 2009-12 ,pp. : 269-275

Bentham Science Publishers

Access to resources Recommend Favorite

Medizin: PCSK9 als neue Zielstruktur

By Schultz Joachim  

PHARMAKON, Vol. 1, Iss. 5, 2013-09 ,pp. : 372-373

Govi-Verlag

Access to resources Recommend Favorite